Study of NouvNeu001 for Multiple System Atrophy
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests a new injection called NouvNeu001 for people with Multiple System Atrophy (MSA). The goal is to see if it can help control symptoms that standard treatments aren't managing well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 70 years old.
- You have a confirmed diagnosis of Multiple System Atrophy (MSA).
- Your MSA motor symptoms started within the last 5 years.
- You can walk at least 10 steps without human help (using a cane or walker is fine).
- You do not have dementia or other serious brain disorders.
- You have not received experimental therapies or gene therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This trial tests a new cell therapy called NouvNeu001 for Parkinson's disease. It involves a one-time brain surgery to deliver the treatment, and researchers will check if it's safe and helps with symptoms.
This trial tests a new cell therapy, NouvNeu001, for people with Parkinson's disease who have had symptoms for at least 4 years and are having trouble with their current medications. The goal is to see if this treatment is safe and can improve motor symptoms that are not well controlled.
This early-stage trial tests a new biologic treatment called ALT001 in people with multiple system atrophy-cerebellar type (MSA-C), a rare neurological condition affecting balance and coordination. The study focuses on whether ALT001 is safe and whether it shows early signs of helping slow disease progression.
This study is collecting information from patients with multiple system atrophy (a rare neurological condition affecting movement and body functions), Parkinson disease, and healthy volunteers to better understand these conditions. By participating, you help doctors learn more about how these diseases develop and progress.
This study tests whether injecting special dopamine-producing brain cells can help slow or improve symptoms in people with multiple system atrophy, a rare movement disorder similar to Parkinson's disease. The trial combines cell transplantation with brain imaging to measure safety and effectiveness.
Hear when a new Multiple System Atrophy - Parkinsonian Subtype (MSA-P) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.